Wei Gu and Emily Crawford contributed equally to this work Background: With widespread adoption of next-generation sequencing (NGS) technologies, the need has arisen for a broadly applicable method to remove unwanted high-abundance species prior to sequencing. We introduce DASH (Depletion of Abundant Sequences by Hybridization), a facile technique for targeted depletion of undesired sequences.
ensuring they are not represented in the final sequencing library ( Figure 1B ). We show that this technique preserves the representational integrity of the non-targeted sequences while increasing overall sensitivity in cell line samples and human metagenomic patient samples. Further, we demonstrate the utility of this system in the context of cancer detection, in which depletion of wild-type sequences increases the detection limit for oncogenic mutant sequences. The DASH technique may be used to deplete specific unwanted sequences from existing Illumina sequencing libraries, PCR amplicon libraries, plasmid collections, phage libraries, and virtually any other existing collection of DNA species.
Existing specific sequence enrichment techniques -such as pull-down methods [5, [12] [13] [14] , ampliconbased methods [3, 15] , COLD-PCR [16] , Competitive Allele-Specific TaqMan PCR (castPCR) [17] , and the classic method of using restriction enzyme digestion on mutant sites [18] -can effectively enrich for targets in sequencing libraries, but these are not useful for discovery of unknown or unpredicted sequences.
Brute force counting methods also exist, such as digital PCR (Pan et al., 2015; Vogelstein and Kinzler, 1999 ), but they are not easy to multiplex across a large panel. While high-throughput sequencing of select regions can be highly multiplexed to detect rare and novel mutations, and barcoded unique identifiers can overcome sequencing error noise [19] , it is costly since the vast majority of the sequencing reads map to non-informative wild-type sequences. A number of sequence-specific RNA depletion methods also currently exist. Illumina's Ribo-Zero rRNA Removal Kit and Ambion's GLOBINclear Kit pull rRNAs and globin mRNAs, respectively, out of total RNA samples using sequence-specific oligos conjugated to magnetic beads. RNAse H-based methods, such as New England BioLab's NEBNext rRNA Depletion Kit similarly mark abundant RNA species with sequencespecific DNA oligos, and then subject them to degradation by RNAse H, which digests RNA/DNA hybrid molecules [20] . These methods are all employed prior to the start of library prep, and are limited to samples containing at least 10-100 ng of RNA. DASH, in contrast, depletes abundant species after complementary DNA (cDNA) amplification, and thus can be utilized for essentially any amount of input sample.
Results
We demonstrate deletion of unwanted mitochondrial ribosomal RNA using DASH first on HeLa cell line RNA (Figure 2A,B ) and then on CSF RNA from patients with pathogens in their CSF, in order to increase sequencing bandwidth of useful data. Selection of rRNA sgRNA targets was based on examining coverage plots for standard RNA-Seq experiments on HeLa cells as well as on several patient CSF samples. Fifty-four sgRNA target sites within this region of the mitochondrial chromosome were chosen, situated approximately every 50 bp over a 2.5 kb region (sequences listed in Supplemental Table 1 ). sgRNA sites are indicated by red arrows in Figure 2B . sgRNAs for these sites were generated as described in the methods section. Coverage of the 12S and 16S mitochondrial rRNA genes was consistently several orders of magnitude higher than the rest of the mitochondrial and non-mitochondrial genes ( Figures 2C and 3) .
To calculate the input ratio of Cas9 and sgRNA to sample nucleic acid, we estimated that 90% of each sample was comprised of the rRNA regions that we targeted, thus our potential substrate makes up 4.5 ng of a 5 ng sample. This corresponds to a target site concentration of 13.8 nM in the 10 µL reaction volume. To assure the most thorough Cas9 activity possible, and given that Cas9 is a single-turnover enzyme in vitro [21] , we used a 100-fold excess of Cas9 protein and a 1,000-fold excess of sgRNA relative to the target. Thus, each 10 µL sample of cDNA generated from a CSF sample contained a final concentration of 1.38 µM Cas9 protein and 13.8 µM sgRNA. In the case of HeLa cDNA, we used only 1 ng per sample, and therefore decreased the Cas9 and sgRNA concentrations by 5-fold.
However, since mitochondrial rRNA sequences represented only 60% of the HeLa samples (compared to 90% for CSF), the HeLa samples contained 150-fold Cas9 and 1,500-fold sgRNA. To examine dose response, we processed additional 1 ng HeLa samples treated with 15-fold Cas9 and 150-fold sgRNA.
Both concentrations were done in triplicate (see Supplemental Figure 1 ).
Reduction of Unwanted Abundant Sequences in HeLa Samples
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We first demonstrate the utility and efficacy of our approach using sequencing libraries prepared from total RNA extracted from HeLa cells. In the untreated samples, reads mapping to 12S and 16S mitochondrial rRNA genes represent 61% of all uniquely-mapped human reads. After DASH treatment, these sequences are reduced to only 0.055% of those reads (Figure 2A 
Enrichment of Non-Targeted Sequences and Analysis of Off-Target Effects in HeLa Samples
This profound depletion of abundant 12S and 16S transcripts increases the available sequencing capacity for the remaining, untargeted transcripts. We quantify this increase by the slope of the regression line fit to the remaining genes, showing a 2.9-fold enrichment in fpkm values for all untreated transcripts. An R 2 coefficient of 0.99 for this regression line indicates strong consistency between replicates with minimal off-target effects ( Figure 2C ).
To confirm that our depletion was specific to only the targeted mitochondrial sequences, we calculated the changes in fpkm values across all genes in the treated and untreated samples and identified those genes that were significantly diminished (> 2 standard deviations) relative to their control values. To overcome issues with stochastic variation at low gene counts/fpkm, we eliminated those genes that, between the three technical replicates at each Cas9 concentration, showed standard deviations in fpkm values greater than 50% of the mean. All of the genes meeting this criterion were present at less than 15 fpkm. Of the remaining genes, only one non-targeted human gene, MT-RNR2-L12, showed significant depletion when compared to the un-treated samples ( Figure 2C ). MT-RNR2-L12 is a pseudogene and shares over 90% sequence identity with a portion of the 16S mitochondrial rRNA gene. Out of the 23 sgRNA sites within the homologous region, 16 of them retain intact PAM sites in 7 MT-RNR2-L12. Of these, seven have perfectly matching 20mer sgRNA target sites, and the remaining nine each have between one and four mutations (see Supplemental Figure 2 ). Depletion of this gene is therefore an expected consequence of our sgRNA choices.
Reduction of Unwanted Abundant Sequences in CSF Samples
We next tested the utility of our method when applied to clinically relevant samples. In the case of pathogen detection in patient samples, the microbial transcripts are typically low in number and become greatly outnumbered by human host sequences. As a result, sequencing depth must be drastically increased to confidently detect such small minority sequence populations. We reasoned that depletion of unwanted high-abundance sequences from patient libraries could result in increased representation of pathogen-specific sequence reads. We thus integrated the DASH method with our in-house metagenomic deep sequencing diagnostic pipeline for patients with meningeal inflammation (i.e., meningitis) or brain inflammation (i.e., encephalitis) likely due to an infectious agent or pathogen. Figure   3 and Table 1 summarize the results of this analysis. In the case of a patient with meningoencephalitis whose CSF was previously shown to be infected with the amoeba Balamuthia mandrillaris [22] , diagnosis was originally made by identification of a small fraction (<0.1%) of reads aligning to specific regions of the B. mandrillaris 16S mitochondrial gene. After DASH treatment, human mitochondrial 12S and 16S genes were reduced by an order of magnitude, and sequencing coverage of the B. mandrillaris 16S fragment increased 2.9-fold. Notably, B. mandrillaris is a eukaryotic organism, yet depletion of the human 16S gene by DASH did not have off target effects on the 16S B. mandrillaris mitochondrial gene. Similarly, patient CSF samples with confirmed Taenia solium (pork tapeworm) and
Cryptococcus neoformans (fungus) infections showed 3.9 and 2-fold increases in coverage of the 18S genes of T. solium and C. neoformans, respectively, the detection of which was crucial in the initial diagnoses. The observed increases in relative signal can be translated into either a sequencing cost savings or a higher sensitivity that may be useful clinically for earlier detection of infections.
Reduction of Wild-type Background for Detection of the KRAS G12D (c.35G>A) Mutation in
Human Cancer Samples
Specific driver mutations known to promote cancer evolution and at times to make up the genetic definition of malignant subtypes are important for diagnosis and targeted therapeutics (i.e. precision medicine). In complex samples isolated from biopsies or cell-free body fluids such as plasma, wild-type DNA sequences often overwhelm the signal from mutant DNA, making the application of traditional Sanger sequencing challenging [2, 3, 23] . For NGS, detection of minority alleles requires additional sequencing depth and therefore increases cost. We reasoned that the DASH technique could be applied to increase mutation detection from a PCR amplicon derived from a patient sample. We chose to focus on depletion of the wild-type allele of KRAS at the glycine 12 position, a hotspot of frequent driver mutations across a variety of malignancies [24] [25] [26] . This is an ideal site for DASH, because all codons encoding the wild-type glycine residue contain a PAM site (NGG), while any mutation that alters that residue (e.g., c.35G>A, p.G12D) ablates the PAM site and is thus uncleavable by Cas9 (see Figure   4A ). This will be true of any mutation that changes a glycine (codons GGA, GGC, GGG, and GGT) or a proline (codons CCA, CCC, CCG, and CCT) to any other amino acid. Furthermore, it is relevant to the ubiquitous C>T nucleotide change found in germline mutations as well as somatic cancer mutations [27] . Targeting of other mutations will likely be possible in the near future with reengineered CRISPR nucleases or those that come from alternative species and have different PAM site specificities [28, 29] .
The sequence of the sgRNA designed to target the KRAS G12D PAM site is listed in Supplemental Table 1 , as is the non-human sequence used for the negative control sgRNA. Both were transcribed from a DNA template by T7 RNA polymerase, purified, and complexed with Cas9 as described in the Methods section. Samples were prepared by mixing sheared genomic DNA from a healthy individual (with wild-type KRAS genotype confirmed with digital PCR) and KRAS G12D genomic DNA to achieve mutant to wild type allelic ratios of 1:10, 1:100, and 1:1,000, and 0:1. For each mixture, 25 ng of a DNA mixture was incubated with 25 nM Cas9 pre-complexed with 25 nM of sgRNA targeting KRAS G12D.
This concentration is high relative to the concentration of target molecules, but empirically we found it to be the most efficient ratio. We hypothesize that this may be due to non-cleaving Cas9 interactions with the rest of the human genome [21] , which effectively reduce the Cas9 concentration at the cleavage site.
Samples were subsequently heated to 95°C for 15 minutes in a thermocycler to deactivate Cas9 (Methods). Droplet digital PCR (ddPCR) was used to count wild-type and mutant alleles using the primers and TaqMan probes depicted in Figure 4A and described in the Methods section. All samples were processed in triplicate. Samples incubated with or without Cas9 complexed to a non-human sgRNA target show the expected percentages of mutant allele: approximately 10%, 1%, and 0.1% for the 1:10, 1:100, and 1:1,000 initial mixtures respectively ( Figure 4B ). With addition of Cas9 targeted to KRAS, the wild-type allele count drops nearly two orders of magnitude (purple bars in Figure 4B ), while virtually no change is observed in number of mutant alleles (blue bars). This confirms the high specificity of Cas9 for the NGG of the PAM site.
With the addition of DASH targeted to KRAS G12, the percentage of mutant allele jumps from 10% to 81%, from 1% to 30%, and from 0.1% to 6% ( Figure 4C ). This corresponds to 10-fold, 31-fold and 65fold representational increases for the mutant allele, respectively. As expected, there was virtually no detection of mutant alleles in the wild type-only samples both with and without DASH treatment (one droplet in one of three no DASH wild type-only samples).
Discussion
In this paper we have introduced DASH, a technique that leverages in vitro Cas9 ribonucleoprotein (RNP) activity to deplete specific unwanted high-abundance sequences which results in the enrichment of rare and less abundant sequences in NGS libraries or amplicon pools.
While the procedure may be easily generalized, we developed DASH to address current limitations in metagenomic pathogen detection and discovery, where the sequence abundance of an etiologic agent may be present as a minuscule fraction of the total. For example, infectious encephalitis is a syndrome caused by well over 100 pathogens ranging from viruses, fungi, bacteria and parasites. Because of the sheer number of diagnostic possibilities and the typically low pathogen load present in cerebrospinal fluid (CSF), more than half of encephalitis patients never have an etiologic agent identified [30] . We have demonstrated that NGS is a powerful tool for identifying infections, but as the B. mandrillaris meningoencephalitis case demonstrates, the vast majority of sequence reads are "wasted" resequencing high abundance human transcripts. In this case, we have shown that DASH depletes with incredible specificity the small number of human RNA transcripts that comprise the bulk of the NGS library, thereby lowering the required sequencing depth to detect non-human sequences and enriching the proportion of non-human (Balamuthia) reads in the metagenomic dataset.
In the case of infectious agents, it is possible to directly enrich rare sequences by hybridization to DNA microarrays [31] or beads [12] . However, these approaches rely on sequence similarity between the target and the probe and therefore may miss highly divergent or unanticipated species. Furthermore, the complexity and cost of these approaches will continue to increase with the known spectrum of possible agents or targets. In contrast, the identity and abundance of unwanted sequences in most human tissues and sample types has been well described in scores of previous transcriptome profiling projects [20] , and therefore optimized collections of sgRNAs for DASH depletion are likely to remain stable.
DASH may also enhance the detection of rare mutant alleles that are important for liquid biopsy cancer diagnostics. Allelic depletion with DASH increases the signal (oncogenic mutant allele) to noise (wildtype allele) by more than 60 fold when studying the KRAS hotspot mutant p.G12D. With the rapidly growing number of oncologic therapies that target particular cancer mutations, sensitive and noninvasive techniques for cancer allele detection are increasingly relevant for optimizing the care of these patients [23] . These same techniques are also becoming increasingly important for diagnosis of earlier stage (and generally more curable) cancers as well as the detection of cancer recurrence without needing to re-biopsy the patient [2, 14, 32, 33, 33, 34] .
The potential applications of DASH are manifold. Currently, DASH can be customized to deplete any set of defined PAM-adjacent sequences by designing specific libraries of sgRNAs. Given the popularity and promise of CRISPR technologies, we anticipate the adaptation and/or engineering of CRISPR-associated nucleases with more diverse PAM sites [28, 29, 35] . A portfolio of next-generation Cas9-like nucleases would further enable DASH to deplete large and diverse numbers of arbitrarily selected alleles across the genome without constraint. We envision that DASH will be immediately useful for the development of non-invasive diagnostic tools, with applications to low input samples or cell-free DNA, RNA, or methylation targets in body fluids [4, 6, 32, 34, 36, 37] .
Many other NGS applications could also benefit from depletion of specific sequences, including hemoglobin mRNA depletion for RNA-Seq of blood samples [38] and tRNA depletion for ribosome profiling studies. Depletion of pseudogenes or otherwise homologous sequences by small but consistent differences in sequences is also theoretically possible, and may serve to remove ambiguities in clinical high-throughput sequencing. Using DASH to enrich for minority variations in microbial samples may enable early discovery of pathogen drug resistance. Similarly, the application of DASH to the analysis of cell-free DNA may augment our ability to detect early markers of drug resistance in tumors [23] .
Conclusions
Here, we have demonstrated the broad utility of DASH to enhance molecular signals in diagnostics and its potential to serve as an adaptable tool in basic science research. While the degree of regional depletion of mitochondrial rRNA was sufficient for our application, the depletion parameters were not maximized: we used only 54 sgRNA target sites out of about 250 possible S. pyogenes Cas9 sgRNA candidates in the targeted mitochondrial region. Future studies will explore the upper limit of this system while elucidating the most effective sgRNA and CRISPR-associated nuclease selections, which will likely differ based on target and application. Irrespective, depletion of unwanted sequences by DASH is highly generalizable and may effectively lower costs and increase meaningful output across a broad range of sequence-based approaches.
Methods
Generation of cDNA from HeLa cell line and clinical samples
CSF samples were collected under the approval of the institutional review boards of the University of California San Francisco and San Francisco General Hospital. Samples were processed for highthroughput sequencing as previously described [1, 22] . Briefly, amplified cDNAs were made from randomly primed total RNA extracted from 250uL of CSF or 250 pg of HeLa RNA using the NuGEN Ovation v.2 kit (NuGEN, San Carlos, CA) for low nucleic acid content samples. A Nextera protocol (Illumina, San Diego, CA) was used to add on a partial sequencing adapter on both sides. Resulting fractions were again analyzed by Coomassie gel, and those containing purified Cas9 were combined, concentrated, supplemented with glycerol up to a final concentration of 50%, and frozen at -80°C until use. Protein concentration was determined by BCA assay. Yield was approximately 80 mg from 4 L of bacterial culture.
In vitro preparation of the CRISPR/Cas9 complex
sgRNA target sites were selected as described in the main text. DNA templates for sgRNAs based on an optimized scaffold [39] were made with a similar method to that described in [40] For each chosen target, a 60mer oligo was purchased including the 18-base T7 transcription start site, the targeted 
CRISPR/Cas9 treatment
To form the ribonucleoprotein (RNP) complex, Cas9 and the sgRNAs were mixed at the desired ratio with Cas9 buffer (final concentrations of 50 mM Tris pH 8.0, 100 mM NaCl, 10 mM MgCl 2 , and 1 mM TCEP), and incubated at 37°C for 10 minutes. This complex was then mixed with the desired amount of sample cDNA in a total of 20 µL, again in the presence of Cas9 buffer, and incubated for 2 hours at 37°C.
Since Cas9 has high nonspecific affinity for DNA [21] it was necessary to disable and remove the Cas9 before continuing. For the rRNA depletion samples, 1 µL (at >600 mAU/mL) of Proteinase K (Qiagen, Hilden, Germany) was added to each sample which was then incubated for an additional 15 minutes at 37°C. Samples were then expanded to a volume of 100 µL and purified with three phenol:chloroform:isoamyl alcohol extractions followed by one chloroform extraction in 2mL Phase-lock Heavy tubes (5prime, Hilden, Germany). 10 µL of 3M sodium acetate pH 5.5, 3 µL of linear acrylamide and 226 µL of 100% ethanol were added to the 100 µL aqueous phase of each sample. Samples were cooled on ice for 30 minutes. DNA was then pelleted at 4°C for 45 minutes, washed once with 70% ethanol, dried at room temperature and resuspended in 10 µL water.
In the case of the KRAS samples, Cas9 was disabled by heating the sample at 95°C for 15 minutes in a thermocycler and then removed by purifying the sample with a Zymo DNA Clean & Concentrator-5 kit (Zymo Research, Irvine, CA). All reads were quality filtered using PriceSeqFilter v1.2 [43] such that only read pairs with less than 5 ambiguous base calls (defined as N's or positions with < 95% confidence based on Phred score) were retained. Filtered reads were aligned to the hg38 build of the human genome using the STAR aligner (v 2.4.2a) [44] . Gene counts were generated using the Gencode v23 primary annotations. Pathogenspecific alignments to 16S and 18S sequences were accomplished using Bowtie2 [45] ). Per-nucleotide coverage was calculated from alignment (SAM/BAM) files using the SAMtools suite [46] and analyzed with custom iPython [47] scripts utilizing the Pandas data package. Plots were generated with Matplotlib [48] .
High-throughput sequencing and Analysis of sequencing data
Digital PCR of KRAS mutant DNA
KRAS wild-type DNA was obtained from a healthy consenting volunteer. The sample sat until cell separation occurred, and DNA was extracted from the buffy coat with the QIAamp Blood Mini Kit (Qiagen, Hilden, Germany). KRAS G12D genomic DNA from the human leukemia cell line CCRF-CEM was purchased from ATCC (Manassas, VA). All DNA was sheared to an average of 800 bp using a Covaris M220 (Covaris, Woburn, USA) following the manufacturer's recommended settings. Cas9 reactions occurred as described above.
A primer/probe pair was designed with Primer3 [49, 50] Table 1 for relevant data. 
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